Optimization of CAT-354, a therapeutic antibody directed against interleukin-13, using ribosome display.

In this case study, we describe the use of in vitro protein evolution with ribosome display to improve the potency of a human interleukin-13-neutralising antibody by a factor of over 200-fold and derive a therapeutic candidate, CAT-354, for the treatment of asthma. A combination of directed and random mutagenesis enabled the identification of highly potent neutralising antibodies and highlighted the advantage of the ribosome display protein evolution approach in identifying beneficial mutations across the entire sequence space. This chapter describes in detail the process followed to achieve a successful in vitro affinity maturation outcome using ribosome display technology.

[1]  Leeanne Lewis,et al.  Optimisation of antibody affinity by ribosome display using error-prone or site-directed mutagenesis. , 2012, Methods in molecular biology.

[2]  M. Rothenberg,et al.  Inhibition of human interleukin‐13‐induced respiratory and oesophageal inflammation by anti‐human‐interleukin‐13 antibody (CAT‐354) , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  Lorin Roskos,et al.  A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma , 2010, BMC pulmonary medicine.

[4]  J. Reichert.  Antibodies to watch in 2010 , 2010, mAbs.

[5]  V. Roschke,et al.  Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. , 2003, Arthritis and rheumatism.

[6]  R. Karlsson,et al.  Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. , 1991, Journal of immunological methods.

[7]  G. Winter,et al.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation. , 1992, Journal of molecular biology.

[8]  R. Faggioni,et al.  An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. , 2010, British journal of clinical pharmacology.

[9]  J S Tung,et al.  Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. , 1996, Journal of molecular biology.

[10]  A. Cattaneo,et al.  An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. , 1997, Gene.

[11]  A. Plückthun,et al.  In vitro selection and evolution of functional proteins by using ribosome display. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Minter,et al.  Probing a protein–protein interaction by in vitro evolution , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[14]  Frances H. Arnold,et al.  Exploring Nonnatural Evolutionary Pathways by Saturation Mutagenesis: Rapid Improvement of Protein Function , 1999, Journal of Molecular Evolution.